Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2121537 | 1.00 | MAPT (0.60) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL5870000 | 0.87 | ALDH1A1 (0.53) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL6374257 | 0.87 | ALDH1A1 (0.53) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL7369923 | 0.84 | ALDH1A1 (0.50) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL7369922 | 0.84 | ALDH1A1 (0.50) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL6010360 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL28205062 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL28824310 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL6010370 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL7563707 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-102378580-B | Dipeptide as feedstuff additive | EVONIK DEGUSSA GMBH | 2014-06-11 | — | — | CN | claimed |
| CN-102378580-A | Dipeptide as feedstuff additive | EVONIK DEGUSSA GMBH | 2012-03-14 | — | — | CN | claimed |
| EP-2413711-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | Evonik Degussa GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| WO-2011147881-A2 | CYCLIC DIPEPTIDES AS FEEDSTUFF ADDITIVES | EVONIK DEGUSSA GMBH (DE) | 2011-12-01 | — | — | WO | claimed |
| WO-2010112365-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | EVONIK DEGUSSA GMBH (DE) | 2010-10-07 | — | — | WO | claimed |
| EP-1689426-B1 | PHARMACEUTICAL FORMULATIONS FOR THE SUSTAINED RELEASE OF INTERFERONS AND THERAPEUTIC APPLICATIONS THEREOF | FLAMEL TECH SA (FR) | 2009-12-30 | — | — | EP | claimed |
| EP-1689425-B1 | PHARMACEUTICAL FORMULATIONS FOR THE SUSTAINED RELEASE OF ONE OR MORE ACTIVE PRINCIPLES AND THERAPEUTIC APPLICATIONS THEREOF | FLAMEL TECHNOLOGIE SA (FR) | 2009-12-09 | — | — | EP | claimed |
| EP-1567578-B1 | POLYAMINO ACIDS FUNCTIONALIZED BY AT LEAST ONE (OLIGO)AMINO ACID GROUP AND THERAPEUTIC USES | FLAMEL TECH SA (FR) | 2008-06-25 | — | — | EP | claimed |
| US-20070010652-A1 | Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications | STEPHANIE ANGOT, OLIVIER BREYNE, AND YOU-PING CHAN | 2007-01-11 | — | — | US | claimed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | claimed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025062117-A1 | COMPOUNDS FOR NEURODEGENERATIVE DISEASES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230130352-A1 | METHOD OF SCREENING INHIBITORS OF ANTIBIOTIC RESISTANCE AND INHIBITORS OBTAINED THEREBY | INDUSTRY-UNIVERSITY COOPERATION OF USW (KR) | 2023-04-27 | — | — | US | disclosed |
| CN-110809467-B | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022260535-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2022-12-15 | — | — | WO | disclosed |
| US-20220340604-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220267372-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX PHARMACEUTICALS, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200079800-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3615019-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| CN-110809467-A | Modulators of SESTRIN-GATOR2 interaction and uses thereof | 纳维托制药有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-11-22 | — | — | US | disclosed |
| WO-2018200625-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3364958-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| CN-108289866-A | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | 纳维托制药有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-103402998-B | Bifunctional molecules with antibody recruiting and human immunodeficiency virus entry inhibiting activity | 耶鲁大学 | 2017-09-26 | — | — | CN | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| CN-101506224-B | Peptide epoxyketones for proteasome inhibition | ONYX THERAPEUTICS, INC. (US) | 2016-03-30 | — | — | CN | disclosed |
| CN-105237621-A | Compounds for enzyme inhibition | ONYX THERAPEUTICS INC | 2016-01-13 | — | — | CN | disclosed |
| CN-101405294-B | Compounds for Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-102286070-B | Compounds for enzyme inhibition | ONYX THERAPEUTICS INC | 2014-12-10 | — | — | CN | disclosed |
| CN-101014612-B | Compounds for Enzyme Inhibition | ONYX THERAPEUTICS INC | 2014-11-26 | — | — | CN | disclosed |
| CN-101006098-B | Compounds for the inhibition of proteasome enzymes | ONYX THERAPEUTICS, INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| CN-102378580-B | Dipeptide as feedstuff additive | EVONIK DEGUSSA GMBH | 2014-06-11 | — | — | CN | disclosed |
| CN-103554222-A | Compounds for enzyme inhibition | ONYX THERAPEUTICS INC | 2014-02-05 | — | — | CN | disclosed |
| CN-102875642-A | Compounds for enzyme inhibition | PROTEOLIX INC | 2013-01-16 | — | — | CN | disclosed |
| US-20120101050-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101048-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120093732-A1 | ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM | BRACCO SUISSE S.A. (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094929-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| CN-102378580-A | Dipeptide as feedstuff additive | EVONIK DEGUSSA GMBH | 2012-03-14 | — | — | CN | disclosed |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | US | disclosed |
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2413711-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | Evonik Degussa GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| US-8101601-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| CN-102286070-A | Compounds for enzyme inhibition | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011147881-A2 | CYCLIC DIPEPTIDES AS FEEDSTUFF ADDITIVES | EVONIK DEGUSSA GMBH (DE) | 2011-12-01 | — | — | WO | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| WO-2011109355-A1 | COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| CN-102174076-A | Compounds for proteasome enzyme inhibition | PROTEOLIX INC | 2011-09-07 | — | — | CN | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| CN-101044157-B | Compounds for proteasome inhibition | PROTEOLIX INC | 2011-07-13 | — | — | CN | disclosed |
| US-7919572-B2 | Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications | FLAMEL TECHNOLOGIES (FR) | 2011-04-05 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| EP-1781688-B1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-1745064-B1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270026-A2 | Compounds for proteasome enzyme inhibition | Onyx Therapeutics, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| WO-2010112365-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | EVONIK DEGUSSA GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| CN-101405294-A | Compounds for enzyme inhibition | PROTEOLIX INC (US) | 2009-04-08 | — | — | CN | disclosed |
| US-20080063603-A1 | ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM | BRACCO INTERNATIONAL B.V. (NL) | 2008-03-13 | — | — | US | disclosed |
| CN-101044157-A | Compounds for proteasome inhibition | PROTEOLIX INC (US) | 2007-09-26 | — | — | CN | disclosed |
| CN-101014612-A | Compounds for Enzyme Inhibition | PROTEOLIX INC (US) | 2007-08-08 | — | — | CN | disclosed |
| CN-101006098-A | Compounds for the inhibition of proteasome enzymes | PROTEOLIX INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| CN-1319957-C | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| US-20070010652-A1 | Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications | STEPHANIE ANGOT, OLIVIER BREYNE, AND YOU-PING CHAN | 2007-01-11 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| CN-1549809-A | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | ������������ʽ���� | 2004-11-24 | — | — | CN | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| CN-1054599-C | Hydroxamic acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-07-19 | — | — | CN | disclosed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| CN-1082027-A | Hydroxamic acid derivs | HOFFMANN LA ROCHE (CH) | 1994-02-16 | — | — | CN | disclosed |
| CN-1017337-B | PROCESS FOR PREPARING PHOSPHINIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1992-07-08 | — | — | CN | disclosed |
| CN-87101164-A | PHOSPHINIC ACID DERIVATIVES | — | 1988-06-29 | — | — | CN | disclosed |
| CN-87101164-A | PHOSPHINIC ACID DERIVATIVES | — | 1988-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | MAPT 4727/4885ALDH1A1 721/4885MEN1 4426/4885 |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | MAPT 923/4885ALDH1A1 3529/4885MEN1 2000/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | PLG, AADAC, DNPEP | MAPT 4610/4885ALDH1A1 1220/4885MEN1 2634/4885 |
| US-20220267372-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB11 | MAPT 3539/4885ALDH1A1 3215/4885MEN1 3709/4885 |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | MAPT 1498/4885ALDH1A1 1307/4885MEN1 1704/4885 |
| US-20120094929-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | MAPT 4020/4885ALDH1A1 2975/4885MEN1 3389/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | MAPT 4658/4885ALDH1A1 536/4885MEN1 3615/4885 |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20220340604-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | MAPT 1536/4885ALDH1A1 2249/4885MEN1 3177/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | MAPT 4660/4885ALDH1A1 621/4885MEN1 3362/4885 |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | MAPT 4215/4885ALDH1A1 4294/4885MEN1 3968/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | MAPT 4610/4885ALDH1A1 1220/4885MEN1 2634/4885 |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | MAPT 3999/4885ALDH1A1 3059/4885MEN1 3557/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | MAPT 4020/4885ALDH1A1 2975/4885MEN1 3389/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | MAPT 4371/4885ALDH1A1 1058/4885MEN1 2336/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | MAPT 3999/4885ALDH1A1 3059/4885MEN1 3557/4885 |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | MAPT 4020/4885ALDH1A1 2975/4885MEN1 3389/4885 |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | MAPT 4020/4885ALDH1A1 2975/4885MEN1 3389/4885 |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120101048-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | MAPT 4020/4885ALDH1A1 2975/4885MEN1 3389/4885 |
| US-20120101050-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | MAPT 4020/4885ALDH1A1 2975/4885MEN1 3389/4885 |
| US-20200079800-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | MAPT 2268/4885ALDH1A1 3585/4885MEN1 2509/4885 |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | ADORA1, ADORA3, ADORA2A | MAPT 3699/4885ALDH1A1 158/4885MEN1 1018/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | MAPT 4697/4885ALDH1A1 4336/4885MEN1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.